Literature DB >> 22711157

The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life.

Angelo Antonini1, Paolo Barone, Roberto Marconi, Letterio Morgante, Salvatore Zappulla, Francesco Ernesto Pontieri, Silvia Ramat, Maria Gabriella Ceravolo, Giuseppe Meco, Giulio Cicarelli, Massimo Pederzoli, Michela Manfredi, Roberto Ceravolo, Marco Mucchiut, Giampiero Volpe, Giovanni Abbruzzese, Edo Bottacchi, Luigi Bartolomei, Giuseppe Ciacci, Antonino Cannas, Maria Giovanna Randisi, Alfredo Petrone, Mario Baratti, Vincenzo Toni, Giovanni Cossu, Paolo Del Dotto, Anna Rita Bentivoglio, Michele Abrignani, Rossana Scala, Franco Pennisi, Rocco Quatrale, Rosa Maria Gaglio, Alessandra Nicoletti, Michele Perini, Tania Avarello, Antonio Pisani, Augusto Scaglioni, Paolo Emilio Martinelli, Francesco Iemolo, Laura Ferigo, Pasqualino Simone, Paola Soliveri, Biagio Troianiello, Domenico Consoli, Alessandro Mauro, Leonardo Lopiano, Giuseppe Nastasi, Carlo Colosimo.   

Abstract

Non-motor symptoms are gaining relevance in Parkinson's disease (PD) management but little is known about their progression and contribution to deterioration of quality of life. We followed prospectively 707 PD patients (62 % males) for 2 years. We assessed non-motor symptoms referred to 12 different domains, each including 1-10 specific symptoms, as well as motor state (UPDRS), general cognition, and life quality. Hoehn &amp; Yahr (H&amp;Y) stage was used to categorize patient status (I-II mild; III moderate; IV-V severe). We found that individual non-motor symptoms had variable evolution over the 2-year follow-up with sleep, gastrointestinal, attention/memory and skin disturbances (hyperhidrosis and seborrhea) becoming more prevalent and psychiatric, cardiovascular, and respiratory disorders becoming less prevalent. Development of symptoms in the cardiovascular, apathy, urinary, psychiatric, and fatigue domains was associated with significant life-quality worsening (p < 0.0045, alpha with Bonferroni correction). During the observation period, 123 patients (17 %) worsened clinically while 584 were rated as stable. There was a fivefold greater increase in UPDRS motor score in worse compared with stable patients over 24 months (p < 0.0001 vs. baseline both in stable and worse group). The total number of reported non-motor symptoms increased over 24 months in patients with motor worsening compared to stable ones (p < 0.001). Thirty-nine patients died (3.4 % of patients evaluable at baseline) with mean age at death of 74 years. Deceased patients were older, had significantly higher H&amp;Y stage and motor score, and reported a greater number of non-motor symptoms at baseline. In conclusion, overall non-motor symptom progression does not follow motor deterioration, is symptom-specific, and only development of specific domains negatively impacts quality of life. These results have consequences for drug studies targeting non-motor features.

Entities:  

Mesh:

Year:  2012        PMID: 22711157     DOI: 10.1007/s00415-012-6557-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  24 in total

1.  Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Authors:  Paolo Barone; Werner Poewe; Stefan Albrecht; Catherine Debieuvre; Dan Massey; Olivier Rascol; Eduardo Tolosa; Daniel Weintraub
Journal:  Lancet Neurol       Date:  2010-05-07       Impact factor: 44.182

2.  The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire.

Authors:  K Ray Chaudhuri; Cristina Prieto-Jurcynska; Yogini Naidu; Tanya Mitra; Belen Frades-Payo; Susanne Tluk; Anne Ruessmann; Per Odin; Graeme Macphee; Fabrizio Stocchi; William Ondo; Kapil Sethi; Anthony H V Schapira; Juan Carlos Martinez Castrillo; Pablo Martinez-Martin
Journal:  Mov Disord       Date:  2010-04-30       Impact factor: 10.338

3.  The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study.

Authors:  Kallol Ray Chaudhuri; Pablo Martinez-Martin; Richard G Brown; Kapil Sethi; Fabrizio Stocchi; Per Odin; William Ondo; Kazuo Abe; Graeme Macphee; Doug Macmahon; Paolo Barone; Martin Rabey; Alison Forbes; Kieran Breen; Susanne Tluk; Yogini Naidu; Warren Olanow; Adrian J Williams; Sue Thomas; David Rye; Yoshio Tsuboi; Annette Hand; Anthony H V Schapira
Journal:  Mov Disord       Date:  2007-10-15       Impact factor: 10.338

4.  The Frontal Assessment Battery (FAB): normative values in an Italian population sample.

Authors:  I Appollonio; M Leone; V Isella; F Piamarta; T Consoli; M L Villa; E Forapani; A Russo; P Nichelli
Journal:  Neurol Sci       Date:  2005-06       Impact factor: 3.307

5.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

6.  The FAB: a Frontal Assessment Battery at bedside.

Authors:  B Dubois; A Slachevsky; I Litvan; B Pillon
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

7.  Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.

Authors:  Mariese A Hely; John G L Morris; Wayne G J Reid; Robert Trafficante
Journal:  Mov Disord       Date:  2005-02       Impact factor: 10.338

Review 8.  The clinical progression of Parkinson's disease.

Authors:  Werner Poewe; Philipp Mahlknecht
Journal:  Parkinsonism Relat Disord       Date:  2009-12       Impact factor: 4.891

9.  Rate of clinical progression in Parkinson's disease. A prospective study.

Authors:  Anette Schrag; Richard Dodel; Annika Spottke; Bernhard Bornschein; Uwe Siebert; Niall P Quinn
Journal:  Mov Disord       Date:  2007-05-15       Impact factor: 10.338

10.  Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER).

Authors:  Claudia Trenkwalder; Bryan Kies; Monika Rudzinska; Jennifer Fine; Janos Nikl; Krystyna Honczarenko; Peter Dioszeghy; Dennis Hill; Tim Anderson; Vilho Myllyla; Jan Kassubek; Malcolm Steiger; Marco Zucconi; Eduardo Tolosa; Werner Poewe; Erwin Surmann; John Whitesides; Babak Boroojerdi; Kallol Ray Chaudhuri
Journal:  Mov Disord       Date:  2010-11-18       Impact factor: 10.338

View more
  72 in total

1.  Latent growth-curve analysis reveals that worsening Parkinson's disease quality of life is driven by depression.

Authors:  Jacob D Jones; Michael Marsiske; Michael S Okun; Dawn Bowers
Journal:  Neuropsychology       Date:  2014-11-03       Impact factor: 3.295

2.  Unchanged gastric emptying and visceral perception in early Parkinson's disease after a high caloric test meal.

Authors:  L Epprecht; S R Schreglmann; O Goetze; D Woitalla; C R Baumann; D Waldvogel
Journal:  J Neurol       Date:  2015-06-06       Impact factor: 4.849

3.  L-dopa-induced dopamine synthesis and oxidative stress in serotonergic cells.

Authors:  Branden J Stansley; Bryan K Yamamoto
Journal:  Neuropharmacology       Date:  2012-11-27       Impact factor: 5.250

4.  Monitoring of 30 marker candidates in early Parkinson disease as progression markers.

Authors:  Brit Mollenhauer; Johannes Zimmermann; Friederike Sixel-Döring; Niels K Focke; Tamara Wicke; Jens Ebentheuer; Martina Schaumburg; Elisabeth Lang; Ellen Trautmann; Henrik Zetterberg; Peggy Taylor; Tim Friede; Claudia Trenkwalder
Journal:  Neurology       Date:  2016-05-06       Impact factor: 9.910

5.  The role of dispositional mindfulness in a stress-health pathway among Parkinson's disease patients and caregiving partners.

Authors:  Allison Hicks; Kala Phillips; Chelsea Siwik; Paul Salmon; Irene Litvan; Megan E Jablonski; J Vincent Filoteo; Karen Kayser; Sandra E Sephton
Journal:  Qual Life Res       Date:  2019-06-14       Impact factor: 4.147

6.  The MTHFR C677T polymorphism modifies age at onset in Parkinson's disease.

Authors:  Annamaria Vallelunga; Valentina Pegoraro; Manuela Pilleri; Roberta Biundo; Angela De Iuliis; Mauro Marchetti; Silvia Facchini; Patrizia Formento Dojot; Angelo Antonini
Journal:  Neurol Sci       Date:  2013-09-20       Impact factor: 3.307

7.  Do cognition and other non-motor symptoms decline similarly among patients with Parkinson's disease motor subtypes? Findings from a 5-year prospective study.

Authors:  L Arie; Talia Herman; S Shema-Shiratzky; N Giladi; J M Hausdorff
Journal:  J Neurol       Date:  2017-09-06       Impact factor: 4.849

Review 8.  Palliative Care for Parkinson's Spectrum Disorders: an Emerging Approach.

Authors:  Maya Katz
Journal:  Neurotherapeutics       Date:  2021-01-13       Impact factor: 7.620

9.  Is there room for new non-dopaminergic treatments in Parkinson's disease?

Authors:  Manuela Pilleri; Konstantinos Koutsikos; Angelo Antonini
Journal:  J Neural Transm (Vienna)       Date:  2012-12-11       Impact factor: 3.575

10.  Variables associated with physical health-related quality of life in Parkinson's disease patients presenting for deep brain stimulation.

Authors:  Alexandre Paim Diaz; Fernando Cini Freitas; Maria Emília de Oliveira Thais; Fernando Zanela da Silva Areas; Marcelo Liborio Schwarzbold; Rodrigo Debona; Jean Costa Nunes; Ricardo Guarnieri; Daniel Martinez-Ramirez; Rui Daniel Prediger; Aparna Wagle Shukla; Marcelo Neves Linhares; Roger Walz
Journal:  Neurol Sci       Date:  2016-07-25       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.